These results might explain that, even without exogenous TGF-β2, the anti-GAG-β antibody interferes with the interaction of versican with endogenous TGF-β2 and inhibits glioma migration, while HTZ-349 expresses and secretes high levels of TGF-β2 (Figures 1A and 2). This evidence concerns the gene VCAN and glioma.